Kala Pharmaceuticals, Inc.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Waltham Massachusetts United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2014
NCT02163824
First Marketed Drug
2018
loteprednol (lotemax)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Kala Pharmaceuticals, Inc. | KALA PHARMS INC

Active Ingredients

Marketed Drugs (1)

loteprednol (lotemax) (2018)

Drugs in Phase 4 Trials (1)

loteprednol (lotemax) (10 trials)

Drugs in Phase 3 Trials (1)

prednisolone (hydeltra) (1 trial)

Drugs in Phase 2 Trials (1)

bone marrow derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 2)

Cataract (Phase 3)

Conjunctivitis (Phase 3)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Eye Infections (Phase 3)

Inflammation (Phase 3)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 3